Results 11 to 20 of about 27,592 (211)

Effect of Ezetimibe on Glucose Metabolism and Inflammatory Markers in Adipose Tissue

Biomedicines, 2020
Despite numerous studies, the effects of ezetimibe on glucose metabolism are poorly understood. Here, we aimed to investigate the effects of ezetimibe on glucose metabolism and the expression of inflammatory markers.
Yongin Cho, Ryeong-Hyeon Kim, Hyunki Park, Hye Jin Wang, Hyangkyu Lee, Eun Seok Kang   +5 more
doaj   +1 more source

Effect of Combination Therapy with Ezetimibe and Statins versus Statin Monotherapy on Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Medicina, 2023
Background and Objectives: Lipid-lowering agents such as ezetimibe are recommended in uncontrolled hyperlipidemia for primary and secondary prevention of cardiovascular disease.
Ryuk Jun Kwon, Young Hye Cho, Eun Ju Park, Youngin Lee, Sae Rom Lee, Jung In Choi, Sang Yeoup Lee, Soo Min Son   +7 more
doaj   +1 more source

Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway

Heliyon, 2023
Cholesterol levels were strongly associated with tumor progression and metastasis. Targeted cholesterol metabolism has broad prospects in tumor treatment.
Qinyu He, Lingkai Kong, Weiwei Shi, Ding Ma, Kua Liu, Shuwei Yang, Qilei Xin, Chunping Jiang, Junhua Wu   +8 more
doaj   +1 more source

Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Background Studies comparing treatment strategies based on initiation timing—such as starting PCSK9 inhibitor (PCSK9i) therapy sooner versus later after a myocardial infarction (MI)—are prone to immortal time bias. Clone‐censor‐weight methods can address these issues and allow the researcher to emulate a trial in which patients are assigned to
Cars T, Gustafsson S, Chan Q, Dhalwani N, Kent ST, Briggs A, Gale CP, Gitt A, Jukema JW, Steg PG, Sundström J, James S, Hagström E, Brookhart MA.   +13 more
europepmc   +2 more sources

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles. [PDF]

, 2017
Treatment of dyslipidemia patients with lipid-lowering drugs leads to a significant reduction in low-density lipoproteins (LDL) level and a low to moderate level of increase in high-density lipoprotein (HDL) cholesterol in plasma.
Alderete, Benjamin, Amento, Edward P, Kong, Raymond, Liu, David, Lundry, Jason, Madasamy, Shanmugavel, Robinson, J Paul, Wu, Alan HB   +7 more
core   +1 more source

Alterations of intestinal lipoprotein metabolism in diabetes mellitus and metabolic syndrome [PDF]

, 2015
Diabetes and metabolic syndrome are associated with abnormal postprandial lipoprotein metabolism, with a significant delay in the clearance of many lipid parameters, including triglycerides and chylomicrons.
ARCA, Marcello
core   +1 more source

Ezetimibe ameliorates clinical symptoms in a mouse model of ankylosing spondylitis associated with suppression of Th17 differentiation

Frontiers in Immunology, 2022
Ankylosing spondylitis (AS) is a chronic inflammatory disease that causes spinal inflammation and fusion. Although the cause of AS is unknown, genetic factors (e.g., HLA-B27) and environmental factors (e.g., sex, age, and infection) increase the risk of ...
Jeonghyeon Moon, Seon-Yeong Lee, Seon-Yeong Lee, Hyun Sik Na, Hyun Sik Na, Hyun Sik Na, A Ram Lee, A Ram Lee, A Ram Lee, Keun-Hyung Cho, Keun-Hyung Cho, Keun-Hyung Cho, Jeong Won Choi, Jeong Won Choi, Sung-Hwan Park, Mi-La Cho, Mi-La Cho, Mi-La Cho, Mi-La Cho   +18 more
doaj   +1 more source

Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. [PDF]

, 2018
Despite reducing progression and promoting regression of coronary atherosclerosis, statin therapy does not fully address residual cardiovascular (CV) risk.
Brent Muhlestein, J, Budoff, Matthew, Le, Viet T, May, Heidi T, Nelson, John R, Roy, Sion   +5 more
core   +2 more sources

Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance

Frontiers in Cardiovascular Medicine, 2022
BackgroundStatins are the most widely prescribed medication to lower low-density lipoprotein cholesterol (LDL-c). However, a significant portion of patients are unable to tolerate them due to side effects, most commonly muscle related.
Natalie C. Ward, Christopher M. Reid, Gerald F. Watts, Gerald F. Watts   +3 more
doaj   +1 more source

Ezetimibe therapy: mechanism of action and clinical update. [PDF]

, 2012
The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events.
Dayspring, Thomas D, Phan, Binh An P, Toth, Peter P   +2 more
core   +1 more source